Harrow (HROW) Competitors $34.83 +1.09 (+3.23%) Closing price 04:00 PM EasternExtended Trading$35.15 +0.32 (+0.92%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HROW vs. CRSP, MRUS, VKTX, TGTX, ACAD, CYTK, AKRO, KRYS, ADMA, and AAPGShould you be buying Harrow stock or one of its competitors? The main competitors of Harrow include CRISPR Therapeutics (CRSP), Merus (MRUS), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), ACADIA Pharmaceuticals (ACAD), Cytokinetics (CYTK), Akero Therapeutics (AKRO), Krystal Biotech (KRYS), ADMA Biologics (ADMA), and Ascentage Pharma Group International (AAPG). These companies are all part of the "pharmaceutical products" industry. Harrow vs. Its Competitors CRISPR Therapeutics Merus Viking Therapeutics TG Therapeutics ACADIA Pharmaceuticals Cytokinetics Akero Therapeutics Krystal Biotech ADMA Biologics Ascentage Pharma Group International Harrow (NASDAQ:HROW) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations. Do institutionals and insiders hold more shares of HROW or CRSP? 72.8% of Harrow shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 13.7% of Harrow shares are owned by insiders. Comparatively, 4.1% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is HROW or CRSP more profitable? Harrow has a net margin of -4.49% compared to CRISPR Therapeutics' net margin of -1,229.43%. Harrow's return on equity of -2.08% beat CRISPR Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Harrow-4.49% -2.08% -0.34% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Do analysts recommend HROW or CRSP? Harrow presently has a consensus target price of $63.83, suggesting a potential upside of 83.27%. CRISPR Therapeutics has a consensus target price of $71.60, suggesting a potential upside of 26.50%. Given Harrow's stronger consensus rating and higher possible upside, equities analysts plainly believe Harrow is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Harrow 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00CRISPR Therapeutics 1 Sell rating(s) 6 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the media refer more to HROW or CRSP? In the previous week, CRISPR Therapeutics had 29 more articles in the media than Harrow. MarketBeat recorded 45 mentions for CRISPR Therapeutics and 16 mentions for Harrow. CRISPR Therapeutics' average media sentiment score of 0.63 beat Harrow's score of 0.49 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CRISPR Therapeutics 7 Very Positive mention(s) 11 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, HROW or CRSP? Harrow has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.8, suggesting that its share price is 80% more volatile than the S&P 500. Which has preferable valuation and earnings, HROW or CRSP? Harrow has higher revenue and earnings than CRISPR Therapeutics. Harrow is trading at a lower price-to-earnings ratio than CRISPR Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHarrow$199.61M6.40-$17.48M-$0.56-62.20CRISPR Therapeutics$37.31M137.97-$366.25M-$5.43-10.42 SummaryHarrow beats CRISPR Therapeutics on 10 of the 16 factors compared between the two stocks. Get Harrow News Delivered to You Automatically Sign up to receive the latest news and ratings for HROW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HROW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HROW vs. The Competition Export to ExcelMetricHarrowMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.24B$2.42B$5.50B$9.70BDividend YieldN/A1.82%4.64%4.14%P/E Ratio-139.3221.6530.3925.31Price / Sales6.40682.68447.52103.45Price / Cash246.74186.7137.7258.50Price / Book17.864.408.306.01Net Income-$17.48M$31.61M$3.26B$265.10M7 Day Performance4.13%0.29%0.91%1.13%1 Month Performance-0.29%2.34%3.66%2.44%1 Year Performance-1.89%7.08%46.29%27.98% Harrow Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HROWHarrow2.5232 of 5 stars$34.83+3.2%$63.83+83.3%-6.1%$1.24B$199.61M-139.32180News CoverageEarnings ReportGap UpHigh Trading VolumeCRSPCRISPR Therapeutics3.5943 of 5 stars$55.41+0.7%$71.60+29.2%+17.9%$5.00B$37.31M0.00460Trending NewsAnalyst RevisionMRUSMerus2.8645 of 5 stars$64.60+0.9%$88.50+37.0%+27.3%$4.84B$36.13M0.0037Positive NewsEarnings ReportAnalyst RevisionVKTXViking Therapeutics4.0393 of 5 stars$38.20+0.8%$86.92+127.6%-33.2%$4.26BN/A0.0020Positive NewsTGTXTG Therapeutics4.1648 of 5 stars$26.39-1.2%$46.25+75.3%+32.5%$4.24B$329M72.19290ACADACADIA Pharmaceuticals3.9476 of 5 stars$24.82+0.9%$28.88+16.3%+58.8%$4.15B$957.80M18.66510News CoverageEarnings ReportAnalyst RevisionCYTKCytokinetics4.1518 of 5 stars$33.23-2.6%$70.69+112.7%-40.4%$4.08B$18.47M-6.52250Earnings ReportAnalyst UpgradeAKROAkero Therapeutics3.9628 of 5 stars$48.28-4.3%$81.57+69.0%+95.1%$4.02BN/A0.0030Earnings ReportKRYSKrystal Biotech4.7396 of 5 stars$137.54-0.8%$210.22+52.8%-24.5%$4.01B$290.52M28.18210ADMAADMA Biologics4.2379 of 5 stars$16.40-0.7%$27.67+68.7%+2.7%$3.94B$426.45M28.48530Earnings ReportAAPGAscentage Pharma Group InternationalN/A$40.04-4.6%N/AN/A$3.90B$134.35M0.00600News Coverage Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives Merus Alternatives Viking Therapeutics Alternatives TG Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Cytokinetics Alternatives Akero Therapeutics Alternatives Krystal Biotech Alternatives ADMA Biologics Alternatives Ascentage Pharma Group International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HROW) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredElon Musk: “Nothing happens without this…”Lithium has fueled the EV boom, but another resource is even more critical. Without it, over 20 million electr...Behind the Markets | SponsoredSell these stocks now—what to buy insteadSell these stocks now—Here’s what to buy instead Wall Street legend Marc Chaikin says you must know these 3...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access